Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load

in European Journal of Endocrinology
View More View Less
  • 1 Department of Endocrinology and Nutrition, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium

Correspondence should be addressed to D Maiter; Email: dominique.maiter@uclouvain.be
Restricted access

Objectives

We aimed to investigate the clinical, biochemical, histological and radiological characteristics as well as the response to somatostatin analogs (SSA) in a large cohort of acromegaly patients with a paradoxical GH response (PR) to oral glucose tolerance test (OGTT).

Design

Retrospective study.

Methods

Of 110 patients with acromegaly included in our study, 30 (PR+; 27%) had a paradoxical GH increase of more than 25% relative to basal GH levels during OGTT.

Results

At diagnosis, PR+ patients were older than PR− patients (52 ± 16 years vs 44 ± 14 years, P < 0.05) and had smaller pituitary tumors (40% microadenomas vs 19%, P < 0.05), which were less often invasive (17% vs 35%, P < 0.05), overall more secreting (insulin-like growth factor-1 (IGF-1)/tumoral surface: 2.35 ULN/cm2 (0.28–9.06) vs 1.08 (0.17–7.87), P = 0.011), and more often hypointense on T2-weighted MRI (92% vs 48%, P = 0.001). While the rate of remission after surgery was similar in the two groups (69%), a better response to SSA treatment was observed in PR+ patients, either before (IGF-1 reduction of > 50% after 3–6 months in 77% vs 49%, P = 0.023) or after surgery (normalization of IGF-1 in 100% vs 44%, P = 0.011).

Conclusions

Our study demonstrates that in acromegaly, a paradoxical GH increase during OGTT is associated with particular features of somatotroph adenomas and with a better prognosis in terms of response to SSA.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1029 1029 255
Full Text Views 86 86 16
PDF Downloads 156 156 26
  • 1

    Melmed S Acromegaly. In The Pituitary, 4th ed., pp. 423466. Academic Press, 2017.

  • 2

    Bernabeu I, Aller J, Álvarez-Escolá C, Fajardo-Montañana C, Gálvez-Moreno Á, Guillín-Amarelle C, Sesmilo G. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: expert consensus. Endocrinología, Diabetes y Nutrición 2018 65 297305. (https://doi.org/10.1016/j.endinu.2018.01.008)

    • Search Google Scholar
    • Export Citation
  • 3

    Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary 2017 20 3345. (https://doi.org/10.1007/s11102-017-0792-z)

    • Search Google Scholar
    • Export Citation
  • 4

    Ribeiro-Oliveira Jr A, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically active acromegaly. European Journal of Endocrinology 2011 164 1722. (https://doi.org/10.1530/EJE-10-0744)

    • Search Google Scholar
    • Export Citation
  • 5

    Hage M, Kamenický P, Chanson P. Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology 2019 108 244255. (https://doi.org/10.1159/000497214)

    • Search Google Scholar
    • Export Citation
  • 6

    Beck P, Parker ML, Daughaday WH. Paradoxical hypersecretion of growth hormone in response to glucose. Journal of Clinical Endocrinology and Metabolism 1966 26 46346 9. (https://doi.org/10.1210/jcem-26-4-463)

    • Search Google Scholar
    • Export Citation
  • 7

    Hattori N, Shimatsu A, Kato Y, Koshiyama H, Ishikawa Y, Assadian H, Tanoh T, Nagao M, Imura H. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. Journal of Clinical Endocrinology and Metabolism 1990 70 77177 6. (https://doi.org/10.1210/jcem-70-3-771)

    • Search Google Scholar
    • Export Citation
  • 8

    Landis CA, Harsh G, Lyons J, Davis RL, McCormick F, Bourne HR. Clinical characteristics of acromegalic patients whose pituitary tumours contain mutant Gs protein. Journal of Clinical Endocrinology and Metabolism 1990 71 141614 20. (https://doi.org/10.1210/jcem-71-6-1416)

    • Search Google Scholar
    • Export Citation
  • 9

    Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumours. Neurosurgery 1993 33 198203; discussion 203. (https://doi.org/10.1227/00006123-199308000-00003)

    • Search Google Scholar
    • Export Citation
  • 10

    Buchfelder M, Fahlbusch R, Merz T, Symowski H, Adams EF. Clinical correlates in acromegalic patients with pituitary tumours expressing GSP oncogenes. Pituitary 1999 1 18118 5. (https://doi.org/10.1023/a:1009905131334)

    • Search Google Scholar
    • Export Citation
  • 11

    Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M, Monteserin-Garcia JL, Fröhlich B, Ferasin S & Terreni MR et al.The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells. Journal of Neuroendocrinology 2011 23 64164 9. (https://doi.org/10.1111/j.1365-2826.2011.02155.x)

    • Search Google Scholar
    • Export Citation
  • 12

    Scaroni C, Albiger N, Daniele A, Dassie F, Romualdi C, Vazza G, Regazzo D, Ferraù F, Barresi V & Maffeis V et al.Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2019 104 8568 62. (https://doi.org/10.1210/jc.2018-01360)

    • Search Google Scholar
    • Export Citation
  • 13

    Mukai K, Otsuki M, Tamada D, Kitamura T, Hayashi R, Saiki A, Goto Y, Arita H, Oshino S & Morii E et al.Clinical characteristics of acromegalic patients with paradoxical growth hormone response to oral glucose load. Journal of Clinical Endocrinology and Metabolism 2019 104 16371644. (https://doi.org/10.1210/jc.2018-00975)

    • Search Google Scholar
    • Export Citation
  • 14

    Regazzo D, Losa M, Albiger NM, Terreni MR, Vazza G, Ceccato F, Emanuelli E, Denaro L, Scaroni C, Occhi G. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of GSP-somatotropinomas. European Journal of Endocrinology 2017 176 5435 53. (https://doi.org/10.1530/EJE-16-0831)

    • Search Google Scholar
    • Export Citation
  • 15

    Umahara M, Okada S, Ohshima K, Mori M. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly. Endocrine Journal 2003 50 643650. (https://doi.org/10.1507/endocrj.50.643)

    • Search Google Scholar
    • Export Citation
  • 16

    Hage M, Chaligne R, Viengchareun S, Villa C, Salenave S, Bouligand J, Letouzé E, Tosca L, Rouquette A & Tachdjian G et al.Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas. Journal of Clinical Endocrinology and Metabolism 2019 104 17771787. (https://doi.org/10.1210/jc.2018-01504)

    • Search Google Scholar
    • Export Citation
  • 17

    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014 37 (Supplement 1) S81S90. (https://doi.org/10.2337/dc14-S081)

    • Search Google Scholar
    • Export Citation
  • 18

    Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Hormone and Metabolic Research 2016 48 299305. (https://doi.org/10.1055/s-0035-1569277)

    • Search Google Scholar
    • Export Citation
  • 19

    Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D. Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. European Journal of Endocrinology 2018 178 237246. (https://doi.org/10.1530/EJE-17-0965)

    • Search Google Scholar
    • Export Citation
  • 20

    Burlacu MC, Maiter D, Duprez T, Delgrange E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 2019 63 323331. (https://doi.org/10.1007/s12020-018-1765-3)

    • Search Google Scholar
    • Export Citation
  • 21

    Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 2012 77 727 8. (https://doi.org/10.1111/j.1365-2265.2011.04286.x)

    • Search Google Scholar
    • Export Citation
  • 22

    Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML & Briet C et al.T2-weighted MRI signal predicts hormone and tumour responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer 2016 23 871881. (https://doi.org/10.1530/ERC-16-0356)

    • Search Google Scholar
    • Export Citation
  • 23

    Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C & Brue T et al.A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathologica 2013 126 1231 35. (https://doi.org/10.1007/s00401-013-1084-y)

    • Search Google Scholar
    • Export Citation
  • 24

    Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, Auriemma R, Diallo AM, Hulting AL & Ferone D et al.Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocrine-Related Cancer 2017 24 505518. (https://doi.org/10.1530/ERC-17-0253)

    • Search Google Scholar
    • Export Citation
  • 25

    Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam K, Krijger R, Dietel M & El-Naggar A et al.A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology 2018 31 17701786. (https://doi.org/10.1038/s41379-018-0110-y)

    • Search Google Scholar
    • Export Citation
  • 26

    Dogansen SC, Yalin GY, Tanrikulu S, Tekin S, Nizam N, Bilgic B, Sencer S, Yarman S. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 2018 21 347354. (https://doi.org/10.1007/s11102-018-0877-3)

    • Search Google Scholar
    • Export Citation
  • 27

    Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 2003 228 53353 8. (https://doi.org/10.1148/radiol.2282020695)

    • Search Google Scholar
    • Export Citation
  • 28

    Moss CE, Marsh WJ, Parker HE, Ogunnowo-Bada E, Riches CH, Habib AM, Evans ML, Gribble FM, Reimann F. Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia 2012 55 30943103. (https://doi.org/10.1007/s00125-012-2663-5)

    • Search Google Scholar
    • Export Citation
  • 29

    Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing’s syndrome. Hormone and Metabolic Research 2011 43 2872 91. (https://doi.org/10.1055/s-0030-1270523)

    • Search Google Scholar
    • Export Citation
  • 30

    Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J, Raverot G. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumours using immunohistochemical detection with new specific monoclonal antibodies. Human Pathology 2014 45 717 7. (https://doi.org/10.1016/j.humpath.2013.08.007)

    • Search Google Scholar
    • Export Citation
  • 31

    Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2013 16 49049 8. (https://doi.org/10.1007/s11102-012-0445-1)

    • Search Google Scholar
    • Export Citation